CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines…
Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead…
Harmony remains ongoing, with OLE study intended to gain insights into long-term exposure to ADP101 in qualifying patientsMENLO PARK, Calif.,…
-FYARRO™ approved November 22, 2021 and launched February 23, 2022- -FYARRO added to NCCN® Guidelines as the only preferred therapy…
FDA review of NDA for FT218 is ongoing; commercial and launch preparations on-track to support potential commercial launchExpanded the robust portfolio of…
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing…
GATINEAU, Québec, March 17, 2022 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO”, or the “Company”) (TSX: HEXO; NASDAQ: HEXO) plans to…
– DesCAARTes™ trial progressing in cohort A5 with presentation of DSG3-CAART clinical and translational data from cohorts A3 and A4…
London Clinic Will Begin Delivering Ketamine-Assisted Therapy for Addiction & Mental HealthThird Location Adds to Two Existing Operatons in Bristol…
Nym’s Coding Engine Automates Revenue Cycle Management for Level 1 Pediatric Trauma Center, Bringing Greater Accuracy, Efficiency and Speed to…